Genetic Signatures

Genetic Signatures Debt

The Debt of Genetic Signatures (GSS.AX) as of Oct 27, 2026 is 310,000.00 AUD. In the previous year, Debt was 791,000.00 AUD — a change of -60.81% (lower).

Debt

310,000.00AUD

YoY

-60.81%

Last updated:

In 2026, Genetic Signatures's total debt was 310,000.00 AUD, a -60.81% change from the 791,000.00 AUD total debt recorded in the previous year.

The Genetic Signatures Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
741,000.00 AUD
Jan 1, 2020
741,000.00 AUD
Jan 1, 2021
399,000.00 AUD
Jan 1, 2022
34,000.00 AUD
Jan 1, 2023
0.00 AUD
Jan 1, 2024
1.22 M AUD
Jan 1, 2025
791,000.00 AUD
Jan 1, 2026
310,000.00 AUD
The Genetic Signatures Debt history
YEARDebtYoY
310,000.00AUD-60.81%
791,000.00AUD-35.22%
1.22 MAUD—
0.00AUD-100.00%
34,000.00AUD-91.48%
399,000.00AUD-46.15%
741,000.00AUD0.00%
741,000.00AUD—
0.00AUD—
0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Debt Details

Understanding Genetic Signatures's Debt Structure

Genetic Signatures's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Genetic Signatures's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Genetic Signatures’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Genetic Signatures’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Genetic Signatures stock

Debt of Genetic Signatures is 310,000.00 AUD in 2026.

Debt of Genetic Signatures changed from 791,000.00 AUD to 310,000.00 AUD, representing a -60.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Genetic Signatures

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genetic Signatures